{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:57:30Z","timestamp":1770821850031,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ijid.2021.04.014","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T23:11:47Z","timestamp":1618960307000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017\u20132019)"],"prefix":"10.1016","volume":"107","author":[{"given":"Cecilia G.","family":"Carvalhaes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.04.014_bib0005","article-title":"Comparative in vivo efficacies of tedizolid in neutropenic versus immunocompetent murine Streptococcus pneumoniae lung infection models","volume":"61","author":"Abdelraouf","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/JCM.01886-07","article-title":"Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase","volume":"46","author":"Arias","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2021.04.014_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid","volume":"71","author":"Barber","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.diagmicrobio.2016.10.009","article-title":"Surveillance of tedizolid activity and resistance: in vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe","volume":"87","author":"Bensaci","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.014_bib0025","first-page":"2","article-title":"In vitro activity of tedizolid against Gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014\u20132016","volume":"4","author":"Bensaci","year":"2018","journal-title":"J Infect Dis Treat"},{"key":"10.1016\/j.ijid.2021.04.014_bib0030","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/jac\/dkz120","article-title":"Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014\u201317)","volume":"74","author":"Carvalhaes","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0035","volume":"64","author":"Carvalhaes","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0040","series-title":"Active bacterial core surveillance (ABCs) report emerging infections program network, Streptococcus pneumoniae","author":"CDC","year":"2017"},{"key":"10.1016\/j.ijid.2021.04.014_bib0045","series-title":"Antibiotic resistance threats in the United States","author":"CDC","year":"2019"},{"key":"10.1016\/j.ijid.2021.04.014_bib0050","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/AAC.00390-15","article-title":"In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia","volume":"59","author":"Chen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0055","series-title":"M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI","year":"2018"},{"key":"10.1016\/j.ijid.2021.04.014_bib0060","series-title":"M100Ed30. Performance standards for antimcirobial susceptibility testing: 30th informational supplement","author":"CLSI","year":"2020"},{"key":"10.1016\/j.ijid.2021.04.014_bib0065","series-title":"Invasive pneumococcal disease \u2014 annual epidemiological report for 2017","author":"ECDC","year":"2019"},{"key":"10.1016\/j.ijid.2021.04.014_bib0070","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2021.04.014_bib0075","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0","author":"EUCAST","year":"2020"},{"key":"10.1016\/j.ijid.2021.04.014_bib0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/INF.0b013e318201a154","article-title":"Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching","volume":"30","author":"Hanage","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2021.04.014_bib0085","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.014_bib0095","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/jac\/dky513","article-title":"Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia","volume":"74","author":"Kidd","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mcna.2018.12.008","article-title":"Community-acquired pneumonia and hospital-acquired pneumonia","volume":"103","author":"Lanks","year":"2019","journal-title":"Med Clin N Am"},{"key":"10.1016\/j.ijid.2021.04.014_bib0105","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1128\/AAC.01303-12","article-title":"Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model","volume":"56","author":"Lepak","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.04.014_bib0110","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cit616","article-title":"Tedizolid for the management of human infections: in vitro characteristics","volume":"58","author":"Locke","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.04.014_bib0115","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/cid\/cit615","article-title":"Use of pharmacokinetic\/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate","volume":"58","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.014_bib0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2021.04.014_bib0125","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1128\/AAC.02976-14","article-title":"Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011\u20132012): ceftaroline remains active in vitro among beta-lactam agents","volume":"58","author":"Mendes","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0130","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2021.04.014_bib0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4939-9199-0_18","article-title":"The epidemiology and biostatistics of pneumococcus","volume":"1968","author":"Oligbu","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ijid.2021.04.014_bib0140","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/AAC.00881-16","article-title":"Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014","volume":"60","author":"Pfaller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0145","first-page":"188","article-title":"Activity of tedizolid against Gram-positive clinical isolates causing infections in Europe and surrounding areas (2014\u20132015)","volume":"31","author":"Pfaller","year":"2019","journal-title":"J Chem"},{"key":"10.1016\/j.ijid.2021.04.014_bib0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2047-2994-3-16","article-title":"Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: a cost analysis","volume":"3","author":"Reynolds","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijid.2021.04.014_bib0155","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/jac\/dkz074","article-title":"Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance program (1997\u20132016)","volume":"74","author":"Sader","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.04.014_bib0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/ciw300","article-title":"Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes","volume":"63","author":"Self","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.014_bib0165","series-title":"Tedizolid phosphate package insert","author":"SIVEXTRO","year":"2014"},{"key":"10.1016\/j.ijid.2021.04.014_bib0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jinf.2020.07.035","article-title":"Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009\u20132017","volume":"81","author":"Suaya","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2021.04.014_bib0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14787210.2019.1565994","article-title":"Urinary antigen testing in community-acquired pneumonia in adults: an update","volume":"17","author":"Viasus","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2021.04.014_bib0180","series-title":"The top 10 causes of death","author":"WHO","year":"2018"},{"issue":"Suppl. 6","key":"10.1016\/j.ijid.2021.04.014_bib0185","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections \u2014 full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2021.04.014_bib0190","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijid.2021.04.014_bib0195","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1093\/ofid\/ofz359.146","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate (TZD) and linezolid (LZD) for treatment of ventilated Gram-positive (G+) nosocomial pneumonia","volume":"6","author":"Wunderink","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:57:33Z","timestamp":1761119853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221003258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":39,"alternative-id":["S1201971221003258"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.014","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017\u20132019)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}